Zheng Wen

Zheng Wen

Auto-generated profile, based on publicly available information

Zheng Wen

Division of Cardiology, Department of Internal Medicine, Tongji Hospital (Z.Z., M.Z., C.Z., X.G., Z.W., J.W., C.C., D.W.W.), Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
JNJiali Nie
Jiali Nie
QDQuanlu Duan
Quanlu Duan
MHMengying He
Mengying He
XLXianqing Li
Xianqing Li
BWBei Wang
Bei Wang
LNLi Ni
Li Ni

1 March 2018 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
CZChi Zhou
Chi Zhou
JHJin Huang
Jin Huang
QLQing Li
Qing Li
CZChenao Zhan
Chenao Zhan
XXXizhen Xu
Xizhen Xu
DWDaowen Wang
Daowen Wang

17 May 2019 in Aging
Verified
Journal Article
Open access
MHMengying He
Mengying He
JWJin Wang
Jin Wang
ZYZhongwei Yin
Zhongwei Yin
YZYanru Zhao
Yanru Zhao
HHHuiying Hou
Huiying Hou
CCChen Chen
Chen Chen
Multiple studies indicate that microRNAs (miRNAs) are involved in diabetes. However, the roles of miRNA in the target organ damages in diabetes remain unclear. This study investigated the functions of miR-320a in diabetic nephropathy (DN). In this study, db/db mice were used to observe the changes in podocytes and their function in vivo, as well as in cultured mouse podocyte cells (MPC5) exposed to high glucose in vitro. To further explore the role of miR-320a in DN, recombinant adeno-associated viral particle was administered intravenously to manipulate the expression of miR-320a in db/db mice. Overexpression of miR-320a markedly promoted podocyte loss and dysfunction in DN, including mesangial expansion and increased levels of proteinuria, serum creatinine and urea nitrogen. Furthermore, MafB was identified as a direct target of miR-320a through AGO2 co-immunoprecipitation, luciferase reporter assay, and Western blotting. Moreover, re-expression of MafB rescued miR-320a-induced podocyte loss and dysfunction by upregulating the expressions of Nephrin and glutathione peroxidase 3 (Gpx3). Our data indicated that miR-320a aggravated renal disfunction in DN by targeting MafB and downregulating Nephrin and Gpx3 in podocytes, which suggested that miR-320a could be a potential therapeutic target of diabetic nephropathy.

13 October 2023 in Circulation Research
Verified
Journal Article
Closed access
ZZZhou Zhou
Zhou Zhou
MZMin Zhang
Min Zhang
CZChengcheng Zhao
Chengcheng Zhao
XGXu Gao
Xu Gao
ZWZheng Wen
Zheng Wen
DWDaowen Wang
Daowen Wang
Myocarditis is a challenging inflammatory disease of the heart, and better understanding of its pathogenesis is needed to develop specific drug therapies. Epoxyeicosatrienoic acids (EETs), active molecules synthesized by CYP (cytochrome P450) enzymes from arachidonic acids and hydrolyzed to less active dihydroxyeicosatrienoic acids by sEH (soluble epoxide hydrolase), have been attributed anti-inflammatory activity. Here, we investigated whether EETs have immunomodulatory activity and exert protective effects on coxsackie B3 virus–induced myocarditis. Viral infection altered eicosanoid epoxide and diol levels in both patients with myocarditis and in the murine heart and correlated with the increased expression and activity of sEH after coxsackie B3 virus infection. Administration of a sEH inhibitor prevented coxsackie B3 virus–induced cardiac dysfunction and inflammatory infiltration. Importantly, EET/sEH inhibitor treatment attenuated viral infection or improved viral resistance by activating type I IFN (interferon) signaling. At the molecular level, EETs enhanced the interaction between GSK3β (glycogen synthase kinase-3 beta) and TBK1 (TANK-binding kinase 1) to promote IFN-β production. Our findings revealed that EETs and sEH inhibitors prevent the progress of coxsackie B3 virus–induced myocarditis, particularly by promoting viral resistance by increasing IFN production.

26 July 2018 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
CZChi Zhou
Chi Zhou
JHJin Huang
Jin Huang
QLQing Li
Qing Li
CZChenao Zhan
Chenao Zhan
YHYing He
Ying He
DWDaowen Wang
Daowen Wang

1 October 2023 in Hypertension
Verified
Journal Article
Closed access
YWYinhui Wang
Yinhui Wang
JSJia Song
Jia Song
KYKun Yu
Kun Yu
DNDaan Nie
Daan Nie
CZChengcheng Zhao
Chengcheng Zhao
CZChunxia Zhao
Chunxia Zhao
BACKGROUND: Aberrant amino acid metabolism is implicated in cardiac hypertrophy, while the involvement of tryptophan metabolism in pathological cardiac hypertrophy remains elusive. Herein, we aimed to investigate the effect and potential mechanism of IDO1 (indoleamine 2,3-dioxygenase) and its metabolite kynurenine (Kyn) on pathological cardiac hypertrophy. METHODS: Transverse aortic constriction was performed to induce cardiac hypertrophy in IDO1-knockout (KO) mice and AAV9-cTNT-shIDO1 mice. Liquid chromatography–mass spectrometry was used to detect the metabolites of tryptophan-Kyn pathway. Chromatin immunoprecipitation assay and dual luciferase assay were used to validate the binding of protein and DNA. RESULTS: IDO1 expression was upregulated in both human and murine hypertrophic myocardium, alongside with increased IDO1 activity and Kyn content in transverse aortic constriction-induced mice’s hearts using liquid chromatography–mass spectrometry analysis. Myocardial remodeling and heart function were significantly improved in transverse aortic constriction-induced IDO1-KO mice, but were greatly exacerbated with subcutaneous Kyn administration. IDO1 inhibition or Kyn addition confirmed the alleviation or aggravation of hypertrophy in cardiomyocyte treated with isoprenaline, respectively. Mechanistically, IDO1 and metabolite Kyn contributed to pathological hypertrophy via the AhR (aryl hydrocarbon receptor)-GATA4 (GATA binding protein 4) axis. CONCLUSIONS: This study demonstrated that IDO1 deficiency and consequent Kyn insufficiency can protect against pathological cardiac hypertrophy by decreasing GATA4 expression in an AhR-dependent manner.